# Clinical Cancer Research

## Table of Contents

### Highlights of This Issue 937

### SPECIAL FEATURES

#### CCR 20th Anniversary Commentary

- **939** CCR 20th Anniversary Commentary: In the Beginning, There Was PS-341
  Beverly A. Teicher and Kenneth C. Anderson

- **942** CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer
  Clint T. Allen, Barbara Conley, John B. Sunwoo, and Carter Van Waes

#### CCR Translations

- **944** Immunomodulatory Antibody Therapy of Cancer: The Closer, the Better
  Roxana S. Dronca and Haidong Dong
  See related articles, p. 1115 and p. 1127

- **947** Moving from Evaluation to Value in Cancer Care
  Richard L. Schilsky
  See related article, p. 1036

#### CCR Perspectives in Drug Approval

- **950** FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
  Albert Deisseroth, Chia-Wen Ko, Lei Nie, Jeanne F. Zirkelbach, Liang Zhao, Julie Bullock, Nitin Mehrotra, Pedro Del Valle, Haleh Saber, Christopher Sheth, Brenda Gehrze, Robert Justice, Ann Farrell, and Richard Pazdur

#### Molecular Pathways

- **955** Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer
  Rebecca A. Preeus, Robert L. Coleman, Adrian L. Harris, and Anil K. Sood

- **962** Molecular Pathways: Linking Tumor Microenvironment to Epithelial–Mesenchymal Transition in Metastasis
  Hae-Yun Jung, Laurent Fattet, and Jing Yang

- **969** Zebrafish: A New Companion for Translational Research in Oncology
  Jorge Barriuso, Raghavendar Nagaraju, and Adam Hurlstone

- **976** Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non–Small Cell Lung Cancer
  Valsamo K. Anagnostou and Julie R. Brahmer

#### CANCER THERAPY: CLINICAL

- **985** A Phase I Study of Oral ARRY-614, a p38 MAPK/Tie2 Dual Inhibitor, in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes

- **995** CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
  Angela DeMichele, Amy S. Clark, Kay See Tan, Daniel F. Heitjan, Kristi Gamlich, Maryann Gallagher, Priti Lal, Michael Feldman, Paul Zhang, Christopher Colameco, David Lewis, Melissa Langer, Noah Goodman, Susan Domshe, Kerrihi Gogineni, Mark Rosen, Kevin Fox, and Peter O’Dwyer

- **1002** Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors

- **1010** Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions

---

Downloaded from clincancerres.aacrjournals.org on April 14, 2017. © 2015 American Association for Cancer Research.
# Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
</table>
| 1019 | A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response  
Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James C. Yang, Mark E. Dudley, John R. Wunderlich, Richard M. Sherry, Udai S. Kammula, Marybeth S. Hughes, Nicholas P. Restifo, Mark Raffeld, Chyi-Chia R. Lee, Yong F. Li, Mona El-Gamil, and Steven A. Rosenberg |
| 1028 | Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib  
S. Michael Rothenberg, David G. McFadden, Edwin L. Palmer, Gilbert H. Daniels, and Lori J. Wirth |
| 1036 | Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors  
Alberto F. Sobrero, Alessandro Pastorino, Daniel J. Sargent, and Paolo Bruzzi |
| 1044 | A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors  
Andrew J. Wagner, Wels A. Messersmith, M. Naveed Shaik, Sherry Li, Xianxian Zheng, Karen R. McLachlan, Rossano Cesari, Rachel Courtney, Wendy J. Levin, and Anthony B. El-Khoueiry |
| 1052 | Nottingham Clinico-Pathological Response Index (NPR1) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer  
| 1063 | Longitudinal Noninvasive Imaging of Progesterone Receptor as a Predictive Biomarker of Tumor Responsiveness to Estrogen Deprivation Therapy  
Suzman Ruby Chan, Amy M. Fowler, Julie A. Allen, Dong Zhou, Carmen S. Dence, Terry L. Sharp, Nicole M. Fettig, Farrokh Dehdashli, and John A. Katzenellenbogen |
| 1071 | Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial  
Toni K. Choueiri, David J. Figueroa, André P. Fay, Sabina Signoretti, Yuan Liu, Robert Gagnon, Keith Deen, Christopher Carpenter, Peter Benson, Thai H. Ho, Lini Pandite, Paul de Souza, Thomas Powles, and Robert J. Motzer |
| 1078 | Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)  
Stephanie M. Cushman, Chen Jiang, Ace I. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kourosh Owzar, Herbert I. Hurwitz, and Andrew B. Nixon |
| 1087 | Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy  
Pierre Laurent-Puig, Deniz Pekin, Corinne Normand, Steve K. Kotsopoulos, Philippe Nizard, Karla Perez-Toralla, Rachel Rowell, Jeff Olson, Preethi Srinivasan, Delphine Le Corre, Theyy Hor, Zakaria El Harrak, Xin Yu Li, Darren R. Link, Olivier Bouché, Jean-François Emile, Bruno Landi, Valérie Boige, J. Brian Hutchison, and Valerie Taly |
| 1098 | Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers  
| 1106 | Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models  
Kristen Meeze, Sylvie Vincent, Steven Tyler, Elizabeth K. Maza, Andrea R. Delplo, Steve Bottega, Donna McIntosh, Richard Nicoletti, William M. Winston, Sally Weiler, Bin Feng, Jeno Gyuris, and Zhigang Weng |

## PERSONALIZED MEDICINE AND IMAGING

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
</table>
| 521  | Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial  
Toni K. Choueiri, David J. Figueroa, André P. Fay, Sabina Signoretti, Yuan Liu, Robert Gagnon, Keith Deen, Christopher Carpenter, Peter Benson, Thai H. Ho, Lini Pandite, Paul de Souza, Thomas Powles, and Robert J. Motzer |
| 528  | Gene Expression Markers of Efficacy and Resistance to Cetuximab Treatment in Metastatic Colorectal Cancer: Results from CALGB 80203 (Alliance)  
Stephanie M. Cushman, Chen Jiang, Ace I. Hatch, Ivo Shterev, Alexander B. Sibley, Donna Niedzwiecki, Alan P. Venook, Kourosh Owzar, Herbert I. Hurwitz, and Andrew B. Nixon |
| 536  | Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy  
Pierre Laurent-Puig, Deniz Pekin, Corinne Normand, Steve K. Kotsopoulos, Philippe Nizard, Karla Perez-Toralla, Rachel Rowell, Jeff Olson, Preethi Srinivasan, Delphine Le Corre, Theyy Hor, Zakaria El Harrak, Xin Yu Li, Darren R. Link, Olivier Bouché, Jean-François Emile, Bruno Landi, Valérie Boige, J. Brian Hutchison, and Valerie Taly |
| 544  | Circulating Tumor Cell Analysis in Metastatic Triple-Negative Breast Cancers  
| 552  | Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models  
Kristen Meeze, Sylvie Vincent, Steven Tyler, Elizabeth K. Maza, Andrea R. Delplo, Steve Bottega, Donna McIntosh, Richard Nicoletti, William M. Winston, Sally Weiler, Bin Feng, Jeno Gyuris, and Zhigang Weng |

## CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
</table>
| 557  | The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell–Dependent Tumor Immunity  
Sara M. Mangesbo, Sissela Broos, Erika Fletcher, Niina Veitonmäki, Christina Furebring, Eva Dahlén, Per Norlén, Malin Lindstedt, Thomas H. Tötterman, and Peter Ellmark |

See related commentary, p. 944
Table of Contents

1127  Curing Mice with Large Tumors by Locally Delivering Combinations of Immunomodulatory Antibodies
Min Dai, Yuen Yee Yip, Ingegerd Hellstrom, and Karl Erik Hellstrom
See related commentary, p. 944

1139  Activity of MM-398, Nanoliposomal Irinotecan (nal-IRI), in Ewing’s Family Tumor Xenografts Is Associated with High Exposure of Tumor to Drug and High SLFN11 Expression
Min H. Kang, Jing Wang, Monish R. Makena, Joo-Sang Lee, Nancy Paz, Connor P. Hall, Michael M. Song, Ruben I. Calderon, Riza E. Cruz, Ashly Hindle, Winford Ko, Jonathan B. Fitzgerald, Daryl C. Drummond, Timothy J. Triche, and C. Patrick Reynolds

1151  Radiotherapy Combined with the Immunocytokine L19-IL2 Provides Long-lasting Antitumor Effects

1161  Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin
Sevim Dalva-Aydemir, Richa Bajpai, Maylyn Martinez, Kehinde U.A. Adekola, Irawati Kandela, Changyong Wei, Seema Singhal, Jennifer E. Koblinski, Noopur S. Raje, Steven T. Rosen, and Mala Shanmugam

1172  Patient-Derived Xenografts from Non–Small Cell Lung Cancer Brain Metastases Are Valuable Translational Platforms for the Development of Personalized Targeted Therapy
Hye Won Lee, Jung-il Lee, Je-Gun Shim, Kyeung Min Joo, and Do-Hyun Nam

1183  Integrinβ6-Targeted Immunoliposomes Mediate Tumor-Specific Drug Delivery and Enhance Therapeutic Efficacy in Colon Carcinoma
Benjia Liang, Muhammad Shahbaz, Yang Wang, Huijie Gao, Ruliang Fang, Zhenghuan Niu, Song Liu, Ben Wang, Qi Sun, Weibo Niu, Enya Liu, Bayong Wang, and Jun Niu

1196  Epigenetics Markers of Metastasis and HPV-Induced Tumorigenesis in Penile Cancer
Andrew Feber, Manit Arya, Patricia de Winter, Muhammad Saqib, Raj Nigam, Peter R. Malone, Wei Shen Tan, Simon Rodney, Matthias Lechner, Alex Freeman, Charles Jameson, Asif Muneer, Stephan Beck, and John D. Kelly

1207  A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Kristine Kleivi Sahilberg, Giulia Bottai, Bjørn Naume, Barbara Burwinkel, George A. Calin, Anne-Lise Berresen-Dale, and Libero Santarpia

1215  Sonic Hedgehog and Gli1 Expression Predict Outcome in Resected Pancreatic Adenocarcinoma
Raphael Maréchal, Jean-Baptiste Bachet, Annabelle Calomme, Pieter Demetter, Jean Robert Delpero, Magali Svcek, Jérôme Cros, Armelle Bardier-Dupuis, Francesco Puleo, Geneviève Monges, Pascal Hammel, Christophe Louvet, François Paye, Philippe Bachelier, Yves Patrice Le Treut, Jean-Christophe Vaillant, Alain Sauvanet, Thierry André, Isabelle Salmon, Jacques Devière, Jean-François Emile, and Jean-Luc Van Laethem

1225  Direct Serum Assay for Cell-Free Bmi-1 mRNA and Its Potential Diagnostic and Prognostic Value for Colorectal Cancer
Xin Zhang, Xiaoyun Yang, Yanli Zhang, Xinfeng Liu, Guixi Zheng, Yongmei Yang, Lili Wang, Lutao Du, and Chuanxin Wang

BIOLOGY OF HUMAN TUMORS

AC icon indicates Author Choice
CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org
For more information please visit www.aacrjournals.org
ABOUT THE COVER

The cover shows a section of a tumor biopsy from mice with the SW1 melanoma, which were treated with an anti-CTLA4/PD-1/CD137 mAb combination. Immunohistochemical staining shows a dramatic decrease of tumor-infiltrating CD19 cells. For details, see the article by Dai and colleagues on page 1127 of this issue.